Potentiation of Available Antibiotics by Targeting Resistance – An Emerging Trend in Tuberculosis Drug Development by Kerstin A. Wolff et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Potentiation of Available Antibiotics 
by Targeting Resistance – An Emerging 
Trend in Tuberculosis Drug Development 
Kerstin A. Wolff*, Marissa Sherman* and Liem Nguyen** 
Case Western Reserve University School of Medicine, Cleveland, Ohio  
United States of America 
1. Introduction   
Mycobacterial infections are one of the leading causes of death through disease world-wide 
(World Health Organization, 2010), encompassing infections such as tuberculosis (TB), 
leprosy, Buruli ulcers, and opportunistic non-tuberculosis mycobacterial (NTM) infections 
in immune-compromised individuals, especially patients with acquired immune deficiency 
syndrome (AIDS). The World Health Organization has estimated that one third of the 
world’s population is currently infected with Mycobacterium tuberculosis, the causative agent 
of TB, although only ten percent of those infected will develop active disease (World Health 
Organization, 2010). Highest TB incidences are located in sub-Saharan Africa and Southeast 
Asia, coinciding with human immunodeficiency virus (HIV) hot spots (World Health 
Organization, 2010).  
The extremely high level of intrinsic resistance to most antimicrobial drug classes exhibited by 
M. tuberculosis has left us with a very limited arsenal of useful anti-TB drugs (Nguyen & 
Thompson, 2006). The five available first-line drugs, isoniazid (INH), rifampicin (RIF), 
ethambutol (EMB), pyrazinamide, and streptomycin, are all more than sixty years old 
(Nguyen & Pieters, 2009, Nguyen & Thompson, 2006). Furthermore, the current standard 
regimen (DOTS) for TB is comprised of six to nine months of daily antibiotic treatment with a 
combination of four out of these five drugs, often leading to poor patient adherence and 
incomplete courses of treatment. The rapid rate of mutations occurring in bacteria in general, 
together with the frequent exposure of M. tuberculosis to sub-optimal doses of drugs, have 
granted ample opportunity for this pathogen to acquire additional resistance by amassing 
sequential mutations in drug-target encoding genes (Nguyen & Pieters, 2009, Nguyen & 
Thompson, 2006). Accordingly, we now face the problem of multiple drug resistant (MDR) 
and extensively drug resistant (XDR) M. tuberculosis strains. MDR strains exhibit resistance to 
at least the two most potent first-line drugs (RIF and INH). Besides RIF and INH, XDR strains 
are resistant to any fluoroquinolones and to at least one of the three injectable second-line 
drugs (capreomycin, kanamycin, and amikacin) (World Health Organization, 2006). Infections 
with such strains require further prolonged and aggressive treatment courses employing 
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combinations of numerous second-line drugs that often exhibit toxic side effects and are 
expensive to administer (Dye, 2000, Nguyen & Thompson, 2006). Moreover, the spread of 
these infections is diminishing our already limited arsenal of effective antibiotics even further 
with which some XDR M. tuberculosis strains have become virtually untreatable with current 
medicines (Gandhi et al., 2006, Jassal & Bishai, 2009, LoBue, 2009). 
The current prevalence of drug-resistant strains poses a dire need for alternative TB 
therapies. Development of completely new TB drugs is both time-intensive and costly. 
Although a few compounds have made their way into pre-clinical or clinical stages, this 
approach thus far has provided us with no newly approved anti-TB drugs. On average, it 
takes twelve to fifteen years and US $500 million to get a new drug from the laboratory to 
the market (Bolten & DeGregorio, 2002). Clearly, the possibility that new resistant strains 
may rapidly occur and diminish the utility of a new drug after approval represents a 
significant risk factor for the development of anti-infective drugs. An alternative approach 
to this pathway is presented by the concept of “targeting resistance”. This drug potentiation 
approach, which uses knowledge of resistance mechanisms to (re)sensitize pathogenic 
bacteria to already available drugs, may become an important trend in the new era of drug 
development for infectious diseases. The coadministration of existing drugs and inhibitors 
that suppress resistance mechanisms allows ineffective drugs to (re)gain their antimicrobial 
activity (Wright, 2000, Wright & Sutherland, 2007) (Figure 1). In the case of M. tuberculosis, 
this approach could be used to rescue and extend the utility of current TB drugs, or make 
use of other available drugs that are currently inactive against the bacillus. The extended 
lifespan of valuable approved antibiotics of known pharmacology, toxicology, and 
treatment schedule, represents a unique advantage of the drug potentiation approach.  
This chapter will explore recent findings that suggest several available drugs as promising 
candidates for resistance-targeted potentiation. Future directions regarding this approach in 
TB-drug development will also be discussed. 
 
 
 
Fig. 1. Concept of drug potentiation by targeting resistance. An active resistance mechanism 
allows survival of bacterial pathogens in the face of an antibiotic(s). A potentiator that 
inhibits the resistance mechanism would (re)sensitize the bacteria to the antibiotic(s), thus 
enhancing antibacterial activity. 
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2. Lactams 
The most widely used group of antibiotics today is the lactams, a broad class of drugs 
including penicillin and penicillin derivatives, cephalosporins, monobactams and 
carbapenems (Figure 2 A), that target bacterial cell wall synthesis at the peptidoglycan layer 
(Koch, 2003, Waxman et al., 1980). Peptidoglycan is the major component of the cell wall in 
both Gram-positive and Gram-negative bacteria and is extensively cross-linked by penicillin-
binding proteins (PBPs), lending it stability (Koch, 2003, Waxman et al., 1980). lactam 
antibiotics are cyclic amides containing a hetero-atomic ring consisting of three carbon atoms, 
and one nitrogen atom (Figure 2 A), mimicking certain precursors of peptidoglycan (Koch, 
2003, Waxman et al., 1980). When PBPs mistakenly use lactams as their substrate rather than 
peptidoglycan precursors, the antibiotics are incorporated irreversibly into the PBP structure, 
inhibiting cross-linking activity (Koch, 2003, Waxman et al., 1980), leading to consequent cell 
lysis in hypotonic environments (Beveridge, 1999, Lee et al., 2001, Severin et al., 1997). 
Although serving as the only successful clinical example of potentiation through targeting 
resistance, inhibitors of lactamases have prolonged the life of lactams for more than 
thirty years (Drawz & Bonomo, 2010). Without these potentiators, many lactams would 
have long become useless against multiple bacterial pathogens. lactams such as penicillin 
are now commonly coadministered with lactamase inhibitors such as clavulanic acid, 
sulbactam, or tazobactam that prevent degradation of lactams, thus sustaining bacterial 
susceptibility to lactams.   
2.1 Lactam resistance mechanisms in Mycobacterium tuberculosis 
In the case of mycobacteria, resistance to lactams involves three main components: 
permeability of the mycobacterial cell wall (Chambers et al., 1995, Jarlier et al., 1991, Jarlier & 
Nikaido, 1990, Kasik & Peacham, 1968), affinity of the drugs to their target PBPs (Chambers 
et al., 1995, Mukherjee et al., 1996), and degradation by lactamase activity (Jarlier et al., 
1991, Quinting et al., 1997). In addition, since M. tuberculosis is an intracellular pathogen, an 
effective TB drug must be able to penetrate the macrophage and phagosomal membranes to 
reach the bacilli residing within.  
Although mycobacteria are classified as Gram-positive bacteria, their cell wall is extremely 
thick and multi-layered with varied hydrophobicity, posing an effective obstacle for the 
entry of most chemical compounds. The peptidoglycan network is covered by an 
arabinogalactan layer, both of which are hydrophilic and likely limit penetration of 
hydrophobic compounds (Brennan & Nikaido, 1995). On top of these aforementioned layers 
is another layer consisting of mycolic acids linked to acyl lipids, which forms a waxy, non-
fluid barrier restricting transport of both hydrophobic and hydrophilic molecules (Liu et al., 
1995). Penetration by diffusion of lactams through the mycobacterial cell wall is hundreds 
of times slower than that of Escherichia coli (Chambers et al., 1995, Kasik & Peacham, 1968). 
However, because of the extremely long generation time of M. tuberculosis, the slow rate of 
drug penetration is enough to allow for half-equilibration over the membrane well before 
the cell divides, making cell wall permeability and therefore drug penetration important but 
not a major determinant of lactam resistance (Chambers et al., 1995, Quinting et al., 1997). 
As for drug target affinity, four major PBPs have been identified in M. tuberculosis, all of 
which bind lactams at therapeutically achievable concentrations (Chambers et al., 1995). 
The 49-kDa PBP from M. smegmatis is also sensitive to several lactams at similar 
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concentrations (Mukherjee et al., 1996). Therefore, target affinity does not significantly 
contribute to the mycobacterial lactam resistance. Cell division in M. tuberculosis is 
extremely slow, only occurring every 15-20 hours. This slow growth contributes both 
negatively and positively to drug resistance. Carbapenem antibiotics, which seem to be the 
most effective lactam with antimycobacterial activity, are relatively unstable and lose 
activity much faster than the mycobacterial growth rate (Watt et al., 1992). It has however 
been shown that a daily antibiotic regimen can compensate for loss of activity and markedly 
increase growth inhibitions in vitro (Watt et al., 1992).  
With drug penetration and target affinity being negligible for lactam resistance in 
mycobacteria, degradation by lactamases constitutes the principal resistance mechanism. 
lactamase activity has been reported in all known mycobacterial species (Kasik, 1979), 
except the non-pathogenic M. fallax, which exhibits hypersusceptibility to lactams 
(Quinting et al., 1997). Mycobacteria, including M. tuberculosis, export lactamases to the 
cell wall via the twin-arginine translocation (Tat) pathway (McDonough et al., 2005, Voladri 
et al., 1998), thus disruption of the Tat transporter leads to lower lactamase activity in M. 
smegmatis culture filtrates and increased lactam susceptibility (McDonough et al., 2005). 
The major lactamase in M. tuberculosis, BlaC, is a member of the Ambler Class-A 
lactamases and exhibits broad substrate specificity, catalysing hydrolysis of both 
cephalosporins and penicillins (Voladri et al., 1998, Wang et al., 2006). This broad substrate 
specificity is attributed to the large and flexible substrate-binding site of this particular 
lactamase (Wang et al., 2006). Two additional lactamase-like proteins, encoded by the 
rv0406c and rv3677c genes, have been identified to provide M. tuberculosis H37Rv with a 
lower lactamase activity (Nampoothiri et al., 2008). Expression of these proteins in E. coli 
confers significant resistance to lactam antibiotics (Nampoothiri et al., 2008).  
In general, mycobacterial lactamases exhibit low-level activity compared to those of other 
pathogenic bacteria. However, because of the slow equilibration of lactams across the 
thick cell wall, this low lactamase activity is effective enough to provide protection to 
mycobacteria from lactam action (Jarlier et al., 1991). When M. fallax in trans expresses the 
lactamase from M. fortuitum, MICs for lactams increase dramatically, indicating that 
lactamase-mediated degradation is the critical contributor to lactam resistance in 
mycobacteria (Quinting et al., 1997). For most bacterial lactamases, lactams of the 
carbapenem subgroup are highly resistant to hydrolysis. Unfortunately, M. tuberculosis BlaC 
shows measurable activity with carbapenem compounds including imipenem, ertapenem, 
doripenem and meropenem, even though imipenem and meropenem seem somewhat more 
effective than other carbapenems and penicillins in antimycobacterial activity (Hugonnet & 
Blanchard, 2007, Tremblay et al., 2010). 
Interestingly, BlaC production in M. tuberculosis is lactam inducible, and controlled by a 
regulatory network that is also present in other Gram-positive bacteria (Sala et al., 2009). The 
transcriptional repressor BlaI, a winged helix regulator, forms homodimers that bind DNA 
at specific recognition sites in the absence of lactam antibiotics (Sala et al., 2009). BlaC is 
the only lactamase in M. tuberculosis whose gene is among the BlaI regulon (Sala et al., 
2009). Exposure to lactams dissociates BlaI from its DNA binding site, lifting its 
suppression on blaC transcription thus allowing the production of BlaC lactamase activity 
(Sala et al., 2009).  
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Fig. 2. (A) Structures of lactams. The lactam ring structure constitutes the base of all 
lactams while the secondary ring structure determines the class. (B) Mechanism of 
reaction between lactamase and clavulanate. The serine residue of the reactive site of 
lactamase reacts with the carbonyl group of clavulanate, followed by breakage of the 
amide bond that results in acylation. The acylation step is followed by the formation of an 
imine and secondary ring opening. Note that the ring opening step does not occur with all 
lactamase inhibitors. 
2.2 Potentiation of lactams in mycobacteria  
Attempts to promote the utility of lactams to treat TB and other mycobacterial infections 
have been continuously explored by many laboratories. Rather than ignoring these 
antibiotics, their antimycobacterial activity could be potentiated by coadministration with 
lactamase inhibitors, as routinely practiced for other bacterial infections. As mycobacterial 
susceptibility to lactams is quite high in the absence of lactamase activity (Flores et al., 
2005, Quinting et al., 1997), effective chemical inactivation of lactamases should similarly 
increase lactam sensitivity in these bacteria. In fact, in vitro studies first showed that three 
FDA-approved inhibitors, sulbactam, tazobactam, and clavulanate, effectively inhibit 
nitrocefin degradation by purified BlaC protein (Hugonnet & Blanchard, 2007, Tremblay et 
al., 2008). While sulbactam inhibits BlaC competitively and reversibly, tazobactam inhibits 
BlaC in a time-dependent manner with reappearing enzyme activity. Interestingly, 
clavulanate forms hydrolytically stable, inactive forms of the enzyme, completely and 
irreversibly inhibiting BlaC in a mechanism in which after acylation of clavulanate, a 
secondary ring-opening leads to reactive intermediates that occupy the active site of the 
enzyme (Figure 2 B) (Hugonnet and Blanchard 2007; Tremblay et al. 2008). Hence, 
clavulanate provides a potential lead for the development of effective lactam potentiators 
for TB. 
Whereas data obtained from the aforementioned in vitro studies are promising, drugs used 
for TB must be able to penetrate the mycobacterial cell wall in order to exert their activity. A 
later in vitro study showed that meropenem/clavulanate combination is very effective in 
killing both aerobically and anaerobically grown M. tuberculosis (Hugonnet et al., 2009). 
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More importantly, the drug combination is also effective against thirteen tested XDR M. 
tuberculosis strains (Hugonnet et al., 2009). Furthermore, studies using mouse peritoneal 
macrophages infected with M. tuberculosis indicated that penetration through neither host 
macrophage nor phagosomal membranes appears to be a problem for lactams and/or 
lactamase inhibitors (Chambers et al., 1995, Prabhakaran et al., 1999). Significant reduction 
of mycobacterial counts in mouse macrophages upon treatment with various combinations 
of lactams and lactamase inhibitors within clinically achievable doses has been 
demonstrated (Chambers et al., 1995, Prabhakaran et al., 1999). Encouraging results were 
also reported in animal models. Although less effective than the first-line anti-TB drug INH, 
imipenem significantly reduced M. tuberculosis counts in the lungs and spleens of infected 
mice (Chambers et al., 2005). As a result, imipenem doubled the survival rate of infected 
mice (35% mortality vs. 70%). While only a very few cases in which TB patients treated with 
lactams in conjunction with or without potentiators have been reported, the results were 
always promising. One study using imipenem alone in MDR-TB patients with poor 
predicted outcomes achieved a 70% cure rate (Chambers et al., 2005). Another study showed 
that treatment of TB patients with an amoxicillin/clavulanate combination significantly 
reduced M. tuberculosis counts with early bactericidal activity comparable to patients treated 
with the frontline drug INH (Chambers et al., 1998). Importantly, a case report recently 
described the successful recovery of an advanced XDR-TB patient treated with 
meropenem/clavulanate in conjunction with other drugs (Dauby et al., 2011).  
In summary, evidence obtained from numerous studies performed in vitro, in animals, and 
in humans, all support that lactams potentiated by lactamase inhibitors could provide 
an effective addition to the treatment of drug resistant TB. 
2.3 Future perspectives 
Much work remains to be done in potentiating lactams for the treatment of mycobacterial 
infections. More existing carbapenems should be tested in combination with various 
lactamase inhibitors. With crystal structures and kinetic data now available (Hugonnet & 
Blanchard, 2007, Hugonnet et al., 2009, Tremblay et al., 2010, Tremblay et al., 2008), rational 
design or high throughput screening should be done to identify better inhibitors that 
specifically target BlaC or the other lactamases of M. tuberculosis.  Similarly, sensitization 
of M. tuberculosis to lactams could be achieved by preventing dissociation of BlaI from its 
binding site on the blaC promoter, thereby repressing the expression of this major 
lactamase in the face of lactam exposure. In other bacteria, BlaI homologs are 
inactivated by proteolytic cleavage at a highly conserved Asparagine-Phenylalanine bond 
located in helix α5, which is also present in M. tuberculosis BlaI (Sala et al., 2009). Although it 
has not been identified yet, the most likely candidate for the inactivating protease is 
predicted to be Rv1845c, a zinc metalloprotease encoded by a gene located adjacent to blaI 
(Sala et al., 2009). If proteolysis of BlaI could be prevented by targeting Rv1845c with 
protease inhitors, the BlaI-mediated repression of blaC could be promoted to render the 
bacilli more susceptible to lactams. Similarly, inhibition of lactamase translocation by 
targeting the Tat transpoter system may also represent a novel strategy for lactam 
potentiation. 
Since very promising results have been obtained with in vitro studies of MDR and XDR M. 
tuberculosis using lactamase inhibitors, more comprehensive and well-structured clinical 
trials with human MDR and XDR TB need to be done in order to affirm the efficacy of these 
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agents for TB treatment. Currently, a phase II clinical trial in 100 TB patients utilizing 
meropenem potentiated by clavulanate is being planned in South Korea (Drug Information 
Online, 2011, Science Centric, 2009). In addition, frequency of dosing will need to be 
determined to improve and maintain effective doses over longer periods of time. One of the 
major obstacles to the effective use of lactams in long course regimens is that currently 
used carbapenems have to be administered intravenously, leading to high costs of treatment 
due to necessary supervision by health care professionals as well as complicating patient 
compliance over the entire course of treatment.  
3. Ethionamide 
Ethionamide (ETH, 2-ethylthioisonicotinamide, or Trecator SC, Figure 3 A) is an important 
component of most current drug regimens used in the treatment of MDR-TB. While an 
effective drug against more than 80% of MDR-TB clinical strains, ETH has a low therapeutic 
index, or margin of safety, characterized by a narrow therapeutic effective concentration 
range (Sood & Panchagnula, 2003, Zimmerman et al., 1984). In other words, it is more 
difficult to prescribe ETH treatment doses that ensure effective treatment outcomes and yet 
avoid toxic side effects (Burns, 1999). The lowest dose of ETH required to inhibit M. 
tuberculosis growth has been shown to elicit adverse side effects such as hepatitis and 
gastrointestinal ailments (Flipo et al., 2011). Discovered in 1956, ETH is a structural 
thioamide analogue of INH and must be metabolically activated in order to form adducts 
with nicotinamide adenine dinucleotide (NAD). The ETH-NAD adducts subsequently 
inhibit InhA, the NADH-dependent enoyl-ACP reductase of the fatty acid biosynthesis type 
II system, allowing ETH to exert its activity against the synthesis of mycolic acids, the major 
component of the tubercle bacilli cell wall  (Brossier et al., 2011, Morlock et al., 2003, Vannelli 
et al., 2002, Vilcheze et al., 2008, Zhang, 2005). 
3.1 Ethionamide resistance mechanisms in mycobacteria 
ETH activation requires an NADPH-specific FAD-containing monooxygenase, encoded by 
ethA, which oxidizes ETH to form the covalent ETH-NAD adducts. The active ETH-NAD 
adducts tightly bind to and inhibit InhA activity (Figure 3 A) (Brossier et al., 2011, DeBarber 
et al., 2000, Frenois et al., 2004, Morlock et al., 2003, Wang et al., 2007). EthA was shown to 
catalyze the conversion of ketones to esters, suggesting its physiological function in mycolic 
acid metabolism of M. tuberculosis (Fraaije et al., 2004). In the majority of ETH resistant M. 
tuberculosis isolates, mutations have been mapped to four principal catagories: (i) mutations 
that alter activity of EthA, (ii) mutations in ethR, the gene located adjacent to ethA, (iii) 
mutations in InhA that prevent binding of the activated drug, and (iv) mutations in the inhA 
promoter region that lead to InhA overexpression, (Banerjee et al., 1994, Baulard et al., 2000, 
Brossier et al., 2011, DeBarber et al., 2000, Morlock et al., 2003). Besides these four main 
catagories, several additional genes (ndh, mshA, and dfrA) might also be involved in ETH 
resistance. For example, mutations in ndh, which encodes a NADH dehydrogenase, may 
result in an increased intracellular concentration of NADH that competitively inhibits the 
binding of ETH-NAD adducts to InhA (Vilcheze et al., 2005). While the connection of ndh 
mutations and ETH resistance has been demonstrated in M. bovis BCG and M. smegmatis, it 
has not been observed in M. tuberculosis (Brossier et al., 2011). mshA encodes a 
glycosyltransferase involved in the biosynthesis of mycothiol that may enhance the ETH 
activation by EthA (Brossier et al., 2011, Vilcheze et al., 2008, Xu et al., 2011). Whereas mshA 
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mutations might be readily identified in vitro under ETH selection pressure, mutations in 
mshA only represent a minority among ETH resistant M. tuberculosis clinical isolates 
(Brossier et al., 2011). Lastly, dfrA encodes the dihydrofolate reductase activity involved in 
folate biosynthesis. As it was suggested that dihydrofolate reductase is inhibited by INH 
adducts (Argyrou et al., 2006), this enzyme may also be targeted by the adducts of ETH. 
Thus far, mutations in dfrA have not been identified among ETH resistant clinical isolates 
(Brossier et al., 2011). 
In summary, the reduced EthA-mediated activation of ETH represents the principal 
molecular mechanism contributing to ETH resistance. Indeed, in trans overexpression of the 
prodrug activator EthA in M. smegmatis leads to increased ETH sensitivity and inhibition of 
mycolic acid synthesis (Morlock et al., 2003, Willand et al., 2009) whereas attempts to 
overexpress EthA in M. tuberculosis have been unsuccessful (DeBarber et al., 2000, Morlock et 
al., 2003). In recent studies, it has been clarified that the production of EthA is negatively 
controlled by the transcriptional regulator EthR, encoded by an adjacent gene (Figure 3B) 
(Baulard et al., 2000, Morlock et al., 2003). In trans overexpression of ethR causes strong 
inhibition of ethA expression, whereas chromosomal inactivation of ethR stimulates ETH 
hypersensitivity (Dover et al., 2004, Engohang-Ndong et al., 2004). Furthermore, 
electrophoretic mobility shift assays and DNA footprinting analysis indicate direct 
interaction of EthR with the ethA promoter (Dover et al., 2004, Engohang-Ndong et al., 2004). 
EthR is a member of the TetR/CamR family of repressors that is suggested to sterically 
inhibit the interaction between RNA polymerase and the affected promoter (Engohang-
Ndong et al., 2004, Frenois et al., 2004, Willand et al., 2009). In fact, M. tuberculosis EthR was 
shown to cooperatively multimerize on a 55-bp operator, OethR, located within the ethA 
promotor, thereby repressing ethA expression (Frenois et al., 2004, Vannelli et al., 2002, 
Weber et al., 2008).  
Similar to other TetR/CamR repressors, recent X-ray crystallographic structures revealed 
that EthR exists as a homodimer organized by two functional domains, each composed of 
nine α-helices (Dover et al., 2004, Frenois et al., 2004, Willand et al., 2009). The amino 
terminus of each DNA binding domain consists of a classical helix-turn-helix motif formed 
by α1, 2, and 3. The remaining six α-helices comprise the carboxy-terminus, which contains 
the ligand-binding site responsible for controlling the conformational changes that prevent 
binding of EthR to OethR. Interactions between α-helices of each monomer form a four-helix 
bundle resulting in dimerization of the repressor. The crystal structures also revealed a 
ligand cocrystallized with EthR (Frenois et al., 2006, Frenois et al., 2004). This ligand, 
hexadecyl octanoate (HexOc), occupies the hydrophobic tunnel of each monomer by means 
of hydrophobic interactions and hydrogen bonds (Willand et al., 2009). In the presence of 
HexOc, the distance between the two DNA binding domains in the EthR structure is 
augmented by 18 Å. As a result, the conformational change impairs the ability of EthR to 
bind to its operator (Frenois et al., 2006, Frenois et al., 2004, Willand et al., 2009). The ligand-
binding domain, embedded in the core domain of each monomer, is characterized as a 
narrow hydrophobic tunnel rich in aromatic residues (Dover et al., 2004, Willand et al., 2009). 
More recently, two ETH resistant isolates expressing two unique mutations in EthR, 
Phenylalanine 110 changed to Leucine and Alanine 95 changed to Threonine, further 
illuminated the derepression mechanism of EthR. Both Phenylalanine 110 (located within 
the α5 helix) and Alanine 95 (located within the vicinity of helices α4 and α5) contribute to 
the ligand-binding domain (Brossier et al., 2011). Based on this wealth of knowledge, recent 
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efforts are being made to develop compounds that could potentially interfere with EthR 
repressor function. Such inhibitors could therefore potentiate the antimycobacterial efficacy 
of ETH and possibly reduce its adverse side effects by allowing lower prescribed doses 
(Flipo et al., 2011). 
 
 
Fig. 3. Ethionamide activation and potentiation. (A) Model of ETH activation by EthA. ETH 
is first oxidized by EthA to a corresponding thioamide S-oxide that is further oxidized to 
form the final cytotoxic species. Although the latter oxidation steps remain unclear, it is 
postulated that thioamide S-oxide is converted to an imidoyl radical (right), which attacks 
NAD+. Following hydrolysis and release of the amine group, the final ETH-NAD adducts 
are formed. Alternatively, the amidoyl anion (left) can serve as the intermediate before the 
NAD attack. Scheme redrawn from (Wang et al., 2007). (B) Potentiation of ETH by targeting 
EthR. Binding of inhibitors releases EthR from its interaction with the ethA promoter. This 
allows for derepression of EthA expression, which is responsible for converting ETH to its 
active form ETH-NAD. The activated drug then binds to InhA and inhibits its activity in 
mycolate biosynthesis. EthR inhibitors could thereby function as ETH potentiators. 
3.2 Potentiation of ethionamide in mycobacteria 
Since ligand binding was shown to affect EthR function in repressing ethA expression, and 
increase susceptibility of M. tuberculosis to ETH (Flipo et al., 2011, Frenois et al., 2006, Frenois 
et al., 2004, Willand et al., 2009), much interest has been invested in determining whether 
synthetic compounds could be utilized to regulate DNA-binding activity of EthR (Weber et 
al., 2008, Willand et al., 2009). Since the DNA-binding domain of EthR is able to 
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accommodate a hydrophobic ester such as HexOc, initial attempts were made using several 
ketones to assay their ability to function as EthR ligands as well as to increase mycobacterial 
ETH sensitivity (Frenois et al., 2004). In vitro experiments demonstrated synergy of 
benzylacetone and ETH on M. smegmatis growth (Fraaije et al., 2004). Whereas benzylacetone 
itself did not display antimycobacterial activity, its addition to ETH used at subinhibitory 
concentrations (5 µg ml-1) produced significant inhibition of mycobacterial growth (Frenois 
et al., 2004).  
As an intracellular pathogen, M. tuberculosis resides within phagosomal compartments of 
host macrophages (Nguyen & Pieters, 2005). Therefore, EthR inhibitors not only have to 
specifically target the repressor but must be able to reach the macrophages’ cytosol (Weber 
et al., 2008). To screen for drug-like ETH potentiators, an EthR-based reporter system was 
first developed by the Fussenegger group (Weber et al., 2008). This elegant mammalian-
based system allows for assessment of not only specificity and bioavailability of tested 
molecules, but also their cytotoxicity to the host cell. A library of hydrophilic esters, the 
primary products of EthA-catalyzed Baeyer-Villiger oxidation of ETH, was synthesized and 
tested for their ability to release EthR from its OethR operator within a mammalian cell, using 
the therein described reporter system. A licensed food additive, 2-phenylethyl-butyrate, was 
found to effectively regulate EthR activity as well as to increase M. tuberculosis susceptibility 
to ETH (Weber et al., 2008). In vitro analysis of ethA transcripts by quantitative real time PCR 
verified that 2-phenylethyl-butyrate dissociates EthR from the ethA promoter in a dose-
dependent manner. To assess bioavailability, the reporter system was transfected into 
human embryonic kidney (HEK) cells that were subsequently implanted into mice. In this 
animal model, orally administered 2-phenylethyl-butyrate effectively reached the target 
cells to activate the reporter gene. Most importantly, 2-phenylethyl-butyrate displayed 
synergistic effects with ETH on the growth inhibitory activity against pathogenic 
mycobacteria (Weber et al., 2008). 
From previous analyses of ligand-binding EthR crystal structures (Dover et al., 2004, Frenois 
et al., 2006, Frenois et al., 2004), the hydrophobic interactions and hydrogen-bonding 
properties of the amphiphilic binding cavity was utilized to design a pharmacophore model 
as a means of isolating moderately lipophilic compounds that could potentially interfere 
with the repressor function of EthR (Willand et al., 2009). The novel pharmacophore model 
was designed as a low-molecular weight structure consisting of two hydrophobic ends 
connected by a 4-6 Å linker. This would, in turn, allow for hydrogen bonding interactions 
with the tunnel’s uncharged polar surface formed by Asparagine 179 and Asparagine 176 
side-chains. From a library of drug-like compounds, 131 compounds fitting the 
pharmacophore model were selected and analyzed for properties relevant for drug 
development such as molecular weight, rotatable bonds, polar surface area, hydrogen bond 
donors and acceptors, etc. (Willand et al., 2009). Surface plasmon resonance and co-
crystallization assays emphasized several compounds with the ability to inhibit EthR-DNA 
interaction. Using this approach, BDM14500, a lead compound comprised of a 1,2,4-
oxadiazole linker, was identified to inhibit EthR-DNA interaction by more than 50%. More 
importantly, inhibition activity of ETH on M. tuberculosis growth is significantly boosted by 
BDM14500 (Willand et al., 2009). The primary data obtained  from studies of BDM14500 
allowed further development of improved EthR ligands. Two thiophen-2-yl-1,2,4-oxadiazole 
analogs of BDM14500, BDM31343 and BDM31381, were synthesized and subjected to 
surface plasmon resonance, co-crystallization, and ETH potentiation assays (Flipo et al., 
2011, Willand et al., 2009). Kinetic analysis showed that BDM31343 and BDM31381 inhibit 
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the interaction of EthR and OethR with IC50 values in the nanomolar to micromolar range, 
indicating their potentially high efficacy. Indeed, in M. bovis BCG culture, BDM31381 
treatment results in a 35-fold increase in the level of ethA mRNA. It is suggested that the 
efficacy of BDM31381 resides in its ability to form an energetically favorable orientation by 
generating a new hydrogen bond between the carbonyl of the ligand and the carboxamide 
of the Asparagine 179 side chain. In fact, MIC assays later confirmed that BDM31343 and 
BDM31381 are both more effective potentiators of ETH activity (Flipo et al., 2011, Willand et 
al., 2009). The addition of BDM31343 or BDM31381 (25 µM) respectively allows a 10 (0.1 vs 1 
µg ml-1 ) or 20 (0.025 vs 0.5 µg ml-1) fold reduction in ETH concentration yet retains identical 
M. tuberculosis growth inhibition activity. In other words, BDM31343 and BDM31381 are 
able to potentiate ETH antimycobacterial activity by factors of 10 and 20, respectively 
(Willand et al., 2009). In vivo, mice infected with M. tuberculosis were treated for 3 weeks with 
ETH alone or in conjunction with BDM31343 or BDM31381. Following treatment, the 
mycobacterial load in mouse lungs was quantified. Whereas the BDM31381/ETH 
combination had only a minor effect on bacterial load compared to control mice treated with 
ETH alone, the combination of BDM31343 with ETH resulted in a significant decrease of M. 
tuberculosis load with three times more efficiency than with ETH treatment alone. TB 
treatment with reduced ETH dosages by combining it with BDM31343 may thus allow for 
efficient elimination of the bacillus without severe side effects (Willand et al., 2009). 
3.3 Summary and future perspectives 
Through the implementation of strategies including X-ray crystallography, pharmacophore 
modeling (Willand et al., 2009), and synthetic mammalian gene circuits (Weber et al., 2008), 
effective potentiators of ETH have been identified. While further in vitro and in vivo analyses 
of these compounds will need to be performed, it is expected that such potential molecules 
will boost activity and allow ETH to be reconsidered as a first-line anti-TB antibiotic (Weber 
et al., 2008, Willand et al., 2009). In addition, because ETH and INH inhibit the same target, 
InhA (Banerjee et al., 1994), ETH potentiation might create an exponential boost for the anti-
TB activity of INH and hence their combination. As the attrition rate of the developmental 
process is enormous (Bolten & DeGregorio, 2002), much work remains to be done in 
preclinical and clinical development and product approval stages in order to bring this 
concept to the clinics. Regardless of this risky process, the results obtained from these 
studies have showcased the potential of this approach in improving the efficacy of existing 
TB-drugs, thus extending their lifespan in TB treatment. Similar studies with other TB-drugs 
need to be encouraged, which will not only help to better understand their mechnisms of 
action and resistance, but also reveal further targets for the drug potentiation approach. 
4. Antifolates 
Folate is a generic name referring to a large group of chemically similar B vitamins that are 
essential for the existence of cells in all kingdoms of life. Whereas the synthetic form, widely 
used as a nutritional supplement, is called folic acid or vitamin B9 (pteroylmonoglutamic 
acid, PteGlu), most naturally occurring folate forms are derived from the reduced molecule 
tetrahydrofolate (H4PteGlu, Figure 4). All of these compounds are comprised of three 
molecular components: a two-ring pteridine nucleus, a para-aminobenzoic acid (pABA) 
group, and one or more glutamate residues attached via amide linkages. These molecules 
vary by the C1 groups attached to the N-5 or/and N-10 positions of H4PteGlu (Figure 4B). 
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Folates are important metabolites indispensable for the development and propagation of all 
organisms. H4PteGlu derivatives are required in reactions that involve the transfer of one-
carbon units (C1 reactions, Figure 4A). These reactions are essential for the biosynthesis of 
purines, thymidine, glycine, panthotenate, methionine, and formyl-methionyl-tRNA, the 
initiator of protein synthesis in bacteria (Blakley, 1969, Green et al., 1996, Selhub, 2002). 
Because these molecules are required for the synthesis of the building blocks of 
macromolecules such as nucleic acids and proteins, folate deficiency hinders cell division 
and consequently results in cell death. In addition, lack of folate derivatives also leads to 
defects in the recycling of homocysteine (Hcy, Figure 4) and S-adenosine methionine (SAM), 
which result in elevated homocysteine concentration (homocysteinemia) and reduced 
cellular methylation activities, respectively. Folates are particularly important during 
periods of rapid cell division and growth (Blakley, 1969, Green et al., 1996).  
 
 
Fig. 4. Folate metabolism and antagonism in bacteria. (A) Simplified interconversions of 
folate derivatives in de novo folate synthesis and one-carbon metabolic network. DHFS, 
dihydrofolate synthase; Gly, glycine; Met, methionine; MS, methionine synthase; Pte, 
pteroate; Ser, serine. (B) Chemical structure of monoglutamylated tetrahydrofolate and its 
derivatives carrying C1 groups at various levels of oxidation attached to N-5 or/and N-10. 
Redrawn from (Waller et al., 2010). (C) Scanning spectrophotometric analysis of MTHFS 
reaction, which converts 5-CHO-H4PteGlu (Abs, 285nm) to 5,10-CH+-H4PteGlu (Abs, 360 
nm), catalyzed by the M. tuberculosis MTHFS homolog, Rv0992c, a novel determinant of 
antifolate resistance.  
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Folate metabolism is generally divided into two stages: biosynthesis (upstream) and 
utilization (downstream) (Figure 4A). The upstream de novo folate biosynthesis involves: (i) 
pterin branch synthesizing the pteridine group from guanosine triphosphate (GTP), (ii) 
synthesis of pABA from chorismate, (iii) condensation of pteridine and pABA to form 
dihydropteroate (H2Pte) and (iv) glutamylation which adds one or more glutamate groups 
to form dihydrofolate (H2PteGlu) that is reduced to form H4PteGlu. The downstream folate 
utilization is usually called one-carbon metabolism in which different active forms of 
H4PteGlu participate in distinct reactions donating or accepting one-carbon units for the 
formation of purines, thymidine, glycine, panthotenate, methionine, and formyl-methionyl 
tRNA (Figure 4).  
Because of the vital role of folates in multiple metabolic processes of the cell, folate 
antagonism has been used successfully in chemotherapeutic treatments of multiple diseases 
including cancers, malaria, psoriasis, rheumatoid arthritis, graft-versus-host disease, and 
bacterial infections (Bertino, 1971, Gorlick et al., 1996, Vinetz, 2010). Folate antagonists 
(antifolates or antifols) have been used extensively for the treatment of infectious diseases 
from the late 1930s till 1960s, but their use has declined because of the emergence of resistant 
strains, their cytotoxicity, and most importantly the introduction of more effective drugs 
(Bertino, 1971, Libecco & Powell, 2004). Nevertheless, combination therapies using 
trimethoprim and sulfonamides to create synergistic effects are still used effectively today to 
treat some infectious diseases such as urinary tract infection, Pneumocystis jiroveci 
pneumonia, shigellosis, and for prophylaxis against recurrent and drug-resistant infections 
(Grim et al., 2005, Libecco & Powell, 2004, Proctor, 2008). The absence of enzymes required 
for a complete de novo folate biosynthesis in humans and other mammals makes this 
pathway an attractive and potential target for the development of novel antimicrobial 
agents (Bermingham & Derrick, 2002). Whereas proteins participating in folate metabolism 
are well known, most current folate antagonists are thought to act on either the biosynthesis 
or the reduction of folate (Bermingham & Derrick, 2002, Gangjee et al., 2007, 2008). Whereas 
trimethoprim and folate analogs such as methotrexate inhibit the reduction step through 
inhibition of dihydrofolate reductases (DHFR), sulfonamides and sulfone drugs are pABA 
analogs that outcompete pABA in the condensation with the pteridin group, catalyzed by 
dihydropteroate synthase (DHPS) (Bermingham & Derrick, 2002, Gangjee et al., 2007, 2008).  
4.1 Folate antagonism in chemotherapies of mycobacterial infections and antifolate 
resistance 
The essentiality of folate-mediated one-carbon metabolism in fundamental metabolic and 
cellular processes has been recognized since the 1940s. Almost immediately after folates had 
been identified as essential metabolic cofactors, antifolate drugs that interfere with the folate 
pathway were developed and found to be effective antimicrobial and antineoplastic agents. 
As seen with other antibiotics, acquired resistance to antifolates in pathogenic bacteria also 
occurred rapidly following their introduction. These resistant forms are typically caused by 
mutations that alter either expression levels or protein structures of the targeted enzymes 
(Bertino, 1971, Libecco & Powell, 2004). DHFR can acquire resistance through point 
mutations of active-site residues, thus altering its affinity for trimethoprim (Adrian & 
Klugman, 1997, Volpato & Pelletier, 2009). While clinical resistant strains frequently show a 
diversity of mutations, residues that are most important for trimethoprim affinity are highly 
conserved among the isolates (Adrian & Klugman, 1997). For example, a point mutation in 
the DHFR gene that changes a conserved Isoleucine residue (Isoleucine 94 in M. tuberculosis 
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DHFR) to Leucine, confers 50-fold higher trimethoprim resistance in Streptococcus 
pneumoniae (Adrian & Klugman, 1997). This mutation is commonly found in DHFR from 
mammalian, parasitic and bacterial resistant isolates (Volpato & Pelletier, 2009). For 
sulfonamide and sulfone drugs, single point mutations at the Serine 53 or Proline 55 
residues within DHPS are found in resistant isolates of M. leprae (Baca et al., 2000, Kai et al., 
1999). The two affected residues are located in the drug binding region of M. tuberculosis 
DHPS and are highly conserved throughout bacteria and protozoa (Baca et al., 2000). 
Combined mutations in DHFR and DHPS encoding genes have been known to confer 
resistance to all available antifolates (Bermingham & Derrick, 2002, Gangjee et al., 2007, 
2008). It is important to note that most current knowledge of trimethoprim and sulfonamide 
resistance comes from studies of bacteria distantly related to M. tuberculosis, and very 
limited information on mechanisms involved in antifolate resistance is available for 
mycobacterial species. With the increasing use of antifolates (Date et al., 2010), a better 
understanding of antifolate resistance mechanisms in M. tuberculosis is urgently needed 
(Koser et al., 2010). 
Although much remains unknown about resistance mechanisms, antifolate drugs have been 
used to treat mycobacterial infections. For example, PAS (p-aminosalycilic acid) is currently 
used as a second-line drug for TB (Rengarajan et al., 2004); the sulfone drug Dapsone has 
been used in monodrug regimens to treat leprosy for many decades (Doull, 1963). 
Interestingly, a recent study suggested that the frontline TB-drug INH may also target folate 
metabolism through the inhibitory action of its adducts on DHFR (Argyrou et al., 2006). In 
addition, recent in vitro studies and a case report proposed that antifolate combinations such 
as those of co-trimoxazole (trimethoprim plus sulfamethoxazole) might be effective against 
TB, thus renewing much interest in the exploitation of antifolates to treat MDR and XDR-TB 
(Forgacs et al., 2009, Ong et al., 2010, Young, 2009). M. tuberculosis clinical strains isolated 
from TB patients were shown to be widely susceptible to clinically achievable concentrations 
of co-trimoxazole (Forgacs et al., 2009), or sulfamethoxazole alone (Ong et al., 2010). 
Importantly, the World Health Organization has recently called for widespread use of co-
trimoxazole in the prophylactic treatment of HIV-AIDS patients to prevent opportunistic 
infections (Date et al., 2010). While this practice shows promise, it is likely to expose 
infectious agents, including M. tuberculosis, to antifolates more frequently, which could lead 
to selection of resistant strains, thus shortening the lifespan of this powerful family of drugs 
(Vinetz, 2010). As in the case of lactams, strategies for potentiation of antifolates should be 
readily available to counterattack upcoming resistant strains, thereby extending their utility 
for TB treatment.  
4.2 Potentiation of antifolates in mycobacteria 
A method for boosting antifolate efficacy by utilizing combinations of drugs that target 
individual steps in folate biosynthesis is already in place. Trimethoprim is commonly 
coadministered with sulfonamides, for example sulfamethoxazole in the co-trimoxazole 
combination, to achieve synergy (Libecco & Powell, 2004) (Figure 4). However, in many 
cases including that of M. tuberculosis, the synergistic effect of trimethoprim on 
sulfonamides remains questioned and inconclusive (Forgacs et al., 2009, Ong et al., 2010, 
Suling et al., 1998). In addition, bacterial strains resistant to both trimethoprim and 
sulfonamides have readily been isolated (Bermingham & Derrick, 2002, Gangjee et al., 2007, 
2008). Therefore, novel potentiation approaches targeting resistance mechanisms might be 
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more effective in both potentiating available antifolates and preventing the emergence of 
resistant strains.  
A recent study aimed at targeting intrinsic antifolate resistance in mycobacteria might reveal 
valuable targets for such resistance-targeted potentiation approaches (Ogwang et al., 2011). 
To identify novel antifolate resistance determinants, a genetic screen was first employed 
using a saturated transposon-insertion library of M. smegmatis. These mutants are 
systematically tested for increased antifolate susceptibility, followed by chemical 
complementation using folate derivatives of both the de novo synthesis and the one-carbon 
interconversion network. This chemogenomic profiling approach allows for identification of 
novel determinants previously unknown to function in mycobacterial intrinsic antifolate 
resistance (Ogwang et al., 2011). Using this non-bias screen, the genome-wide collection of 
antifolate resistance determinants in mycobacteria (mycobacterial antifolate resistome) was 
found to be composed of fifty resistance determinants (unpublished data).  
A novel determinant identified from this screen was further characterized in a recent report 
(Ogwang et al., 2011). The M. smegmatis mutant presented in this report exhibits 
hypersusceptibility to several combinations of trimethoprim/sulfonamides tested (Ogwang 
et al., 2011). For example, its MIC to trimethoprim/sulfachloropyridazine is 64 fold lower 
than that of the parental M. smegmatis strain. The transposon insertion was mapped to a 
gene encoding a hypothetical protein with low homologies to 5,10-methenyl-
tetrahydrofolate synthases (MTHFS, also called 5-formyl-tetrahydrofolate cyclo-ligase, 
EC.6.3.3.2) from other organisms, including the prototype MTHFS first described in humans 
(Ogwang et al., 2011). Cross-species in trans expression of the human MTHFS was shown to 
restore antifolate resistance to the M. smegmatis mutant. A series of genetic knockout and 
complementation studies indicated that the disrupted gene encodes a MTHFS activity 
required for mycobacterial intrinsic antifolate resistance (Ogwang et al., 2011). Absence of 
MTHFS enzymatic activity results in the inability to metabolize folinic acid (5-formyl-
tetrahydrofolate, 5-CHO-H4PteGlu) along with the reduced metabolism of 5-methyl-
tetrahydrofolate (5-CH3-H4PteGlu), two major folate derivatives in the cell (Ogwang et al., 
2011). 5-CHO-H4PteGlu is formed by the hydrolysis of 5,10-CH+-H4PteGlu catalyzed by 
serine hydroxymethyltransferase (SHMT, Figure 4A) (Holmes & Appling, 2002, Stover & 
Schirch, 1990), whereas MTHFS is the only enzyme known to recycle 5-CHO-H4PteGlu back 
to 5,10-CH+-H4PteGlu in an irreversible, ATP-dependent reaction (Figure 4C). As a 
consequence of MTHMS absence in mycobacterial cells, polyglutamylated forms of 5-CHO-
H4PteGlu are elevated up to 80 fold, whereas the corresponding polyglutamylated forms of 
5-CH3-H4PteGlu are reduced (Ogwang et al., 2011). Interestingly, 5-CHO-H4PteGlu is the 
only H4PteGlu derivative whose biological function remains largely unknown (Stover & 
Schirch, 1993). Although it is well known chemically and widely used as a medical agent, 5-
CHO-H4PteGlu does not appear to function as a cofactor in any of the one-carbon metabolic 
reactions thus far known (Stover & Schirch, 1993). Because 5-CHO-H4PteGlu is known as the 
most stable form of reduced folate species in nature, and its presence is increased in plant 
seeds and fungal spores, it was suggested that it might function as a folate storage form 
required for these dormant states of life (Kruschwitz et al., 1994, Shin et al., 1975, Stover & 
Schirch, 1993). In mammals and yeasts, 5-CHO-H4PteGlu comprises 3-10% of total folate, 
whereas its presence may account for up to 50% of total folate in plant mitochondria during 
photorespiration when the glycine to serine flux is accelerated (Goyer et al., 2005, Roje et al., 
2002). In vitro, 5-CHO-H4PteGlu is also a potential inhibitor of SHMT and other enzymes of 
the one-carbon metabolism, thus it may potentially serve to regulate these metabolic 
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reactions (Roje et al., 2002, Stover & Schirch, 1991). Deletion of MTHFS in Arabidopsis leads to 
a 2-8-fold increased accumulation of total 5-CHO-H4PteGlu, 46-fold accumulation of 
glycine, reduced growth and delayed flowering (Goyer et al., 2005). In human cells, 
overexpression of MTHFS lowers folate levels and increases folate turnover, suggesting that 
MTHFS may also function as a folate-degrading enzyme (Anguera et al., 2003).  
The role of MTHFS in intrinsic antifolate resistance was found not only in mycobacteria but 
also in E. coli, a Gram-negative bacterium (Nichols et al., 2011, Ogwang et al., 2011), 
suggesting that this determinant functions ubiquitously among bacteria. Indeed, further 
work confirmed that rv0992c, the gene that encodes the MTHFS homolog in M. tuberculosis, 
is also required for antifolate resistance via its MTHFS enzymatic activity (Figure 4C). 
Pharmaceutical inactivation of MTHFS activity is therefore expected to sensitize M. 
tuberculosis to classical antifolates, including those current TB-drugs that happen to target 
folate pathways (PAS, INH, etc.). This intervention may also allow for reduction of effective 
therapeutic doses, thereby minimizing the cytotoxicity of classical antifolates which has 
been an issue for their widespread use in the clinics. Work is underway to identify specific 
inhibitors of M. tuberculosis MTHFS by rational design and high throughput screening, as 
well as to characterize their antifolate potentiation activity against M. tuberculosis. 
4.3 Future perspectives 
Fundamental studies of molecular mechanisms conferring both acquired and intrinsic 
antifolate resistance in M. tuberculosis and related mycobacteria should be further 
conducted. Knowledge obtained from these studies will be essential for strategic 
implementations of antifolate use for TB, and will reveal valid targets for the resistance-
targeted potentiation of classical antifolates.  
A potential problem for the development of MTHFS inhibitors might be their nonspecific 
inhibition towards human MTHFS. However, the low homologies of MTHFS proteins indicate 
the possibility to identify species-specific inhibitors. Trimethoprim, which specifically inhibits 
bacterial DHFR but not the human counterpart, represents an encouraging example for such 
possibilities. Interestingly, a recent work showed that ygfA, the gene that encodes the MTHFS 
homolog in E. coli, is required for the formation of drug persisters during antibiotic treatments 
(Hansen et al., 2008). Although it remains to be characterized if the function of ygfA in 
antibiotic persister formation is related to its MTHFS activity, a similar role for M. tuberculosis 
rv0992c during TB latent infection is under investigation.  
Although in vitro studies and a case report suggested that co-trimoxazole could be used for 
TB treatment (Forgacs et al., 2009, Ong et al., 2010, Young, 2009), more comprehensive well-
designed trials with TB patients should be done to evaluate the efficacy of this antifolate 
combination. These trials should also address if these drugs may help to shorten the current 
TB regimens.  In addition, new combinations using co-trimoxazole and PAS and/or INH 
should be tested against M. tuberculosis both in vitro and in patients.  
5. Conclusions and future prospects  
The primary goal of this chapter is to assess an emerging approach in TB drug development 
that uses knowledge of resistance mechanisms to sensitize M. tuberculosis to available, 
approved antibiotics (Figure 1) (Wright, 2000, Wright & Sutherland, 2007). Specific 
inhibitors that suppress resistance mechanisms would boost the efficacy of current anti-TB 
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drugs, or potentiate the antimycobacterial activity of currently non-TB antibiotics, thus 
making use of drugs that are already available but have never been used for TB treatment 
before. Proofs of concept have been made in recent years to demonstrate the feasibility of 
this approach in potentiating the antimycobacterial activity of important antibiotics such as 
lactams, ethionamide, and antifolates. It is anticipated that this trend will become 
increasingly important in the future of drug development, not only for TB but any disease 
treated by chemotherapies. As the rate of drug resistance expansion appears far beyond that 
of the current drug developmental process, it is logical that such sustainable approaches 
should be promoted to improve the utility and protection of those effective agents.   
Besides targeting antibiotic resistance mechanisms, currently approved drugs should be 
tested systematically against M. tuberculosis, especially drug resistant strains. Recent work 
showed that many antibiotics that had been thought to be inactive against TB might be 
effective as chemotherapeutic agents for the disease (Forgacs et al., 2009, Hugonnet et al., 
2009, Ong et al., 2010). In addition, drug-drug interactions among current combinatorial 
regimens for TB need to be further investigated. Most of the antibiotic combinations 
developed thus far are mainly aimed at minimizing the development of resistance, but 
disregard possible synergistic or antagonistic effects. Future drug combinations that 
minimize antagonistic effects but maximize synergy among the drugs used may not only 
reduce harmful clinical doses but also shorten treatment schedules, which would help to 
prevent the evolution and spread of antibiotic resistance.  
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